atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics
Posted:
atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced a strategic investment in Beckley Psytech Limited (“Beckley Psytech”), a private clinical-stage biotechnology company dedicated to transforming short-duration psychedelics into effective and rapid-acting medicines for neuropsychiatric conditions.
New York-based Claryx has emerged from stealth with $3.5 million in pre-seed funding.
Outlander VC led the round, with participation from Company Ventures, Boost VC, Neon, Mana Ventures, 640 Oxford and Precursor Ventures.
The funding will help Claryx continue to "build…
Researchers have shown that measurements taken from a person's fingertip could help identify physical patterns associated with stress, anxiety and depression.
The international study, involving experts from Aston University, used a wearable device that shines light into the skin to…
Attendees
Sponsors and Exhibitors
Contact us